Stockreport

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

NKGen Biotech, Inc.  (NKGN) 
PDF The Company’s neurodegenerative clinical program remains on track, with continued advancement of the Alzheimer’s Phase 2 trial and anticipation of Parkinson’s Phase 1/2a [Read more]